Centro Hospitalar De Lisboa Ocidental E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is conducting research focused on cardiovascular diseases, addressing conditions such as heart failure with preserved ejection fraction and atrial fibrillation. Trials aim to assess new anticoagulant strategies and anti‑inflammatory therapies to reduce stroke risk and improve heart failure outcomes.
- Heart failure with preserved ejection fraction and systemic inflammation
- Anticoagulation therapy for atrial fibrillation to prevent stroke
- Inflammation‑targeted treatment to lower cardiovascular mortality
At Centro Hospitalar De Lisboa Ocidental, five investigators are leading these studies, contributing to advances in cardiovascular care in Lisbon.
Eye Diseases
The ophthalmology department is engaged in studies on eye diseases, specifically retinopathy of prematurity. The trial evaluates long‑term safety and visual function of a novel treatment for this condition.
- Retinopathy of prematurity long‑term outcomes
- Visual function assessment in premature infants
- Safety monitoring of new ocular therapy
These investigations are carried out at Centro Hospitalar De Lisboa Ocidental, with a team of five clinicians aiming to improve pediatric eye health across Portugal.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Bayer AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar De Lisboa Ocidental E.P.E.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Oseltamivir and Drug Combinations in Hospitalized Patients with Acute Respiratory Tract Infection: A Randomized Adaptive Platform Trial | Universitair Medisch Centrum Utrecht | Phase III | Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | 2020-03-27 | 2020-03-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.